CellFeb 26, 2026

LUMI-lab: An AI-driven platform for finding ionizable lipids that improve mRNA delivery

mRNA Technology Weekly Brief ↗PubMed ↗DOI ↗

Updated Jun 28, 2026

Abstract

Essence

An AI-robotics platform discovered new ionizable lipids that improved mRNA delivery, including a lead candidate that edited lung epithelial cells in mice.

Evidence

This autonomous discovery platform study used a transformer-based foundation model with active learning to synthesize and screen more than 1,700 lipid nanoparticles, identifying brominated tails as beneficial and a lead lipid, LUMI-6, that achieved 20.3% gene editing in mouse lung epithelial cells after intratracheal dosing.

Caveat

The main results are platform optimization and preclinical mouse and cell-system performance, so they do not show clinical efficacy or generalize beyond the tested delivery setting.

Simplified

Integrating AI with robotics offers a promising approach to molecular discovery and optimization, enabling efficient exploration of vast chemical spaces. However, its application in emerging fields is often constrained by sparse historical data. Here, we introduce LUMI-lab, a self-driving platform that integrates a transformer-based foundation model with an active-learning experiment workflow to address the challenges of data scarcity. To demonstrate its potential, LUMI-lab autonomously synthesized and screened over 1,700 lipid nanoparticles (LNPs), identifying ionizable lipids with enhanced mRNA transfection potency in human bronchial cells. It discovered brominated lipid tails as a feature that improves mRNA delivery. Intratracheal administration of LNPs formulated with LUMI-6, the top-performing lipid, to mice achieved 20.3% gene editing efficacy in lung epithelial cells. These findings demonstrate LUMI-lab as a powerful, data-efficient platform for autonomous discovery and optimization of molecules, highlighting the potential of AI-driven robotic systems to advance next-generation RNA delivery technologies.